Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 20 of 20 matching drugs for HTR3D — including drugs targeting any of its 3 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
melphalan, bcnu, vitamin b12b, vitamin c, ethanol, autologous hematopoietic stem cells HTR3D Direct 2
ethanol, enoxaparin HTR3D Direct 1
amisulpride HTR3D Direct yes 0
clothiapine HTR3D Direct yes 0
dexfenfluramine HTR3D Direct yes 0
dexfenfluramine hydrochloride HTR3D Direct yes 0
tropisetron HTR3D Direct yes 0
zimeldine HTR3D Direct yes 0
zimeldine hydrochloride HTR3D Direct yes 0
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib CSK SSL via CSK 3
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment CSK SSL via CSK 2
afatinib, dasatinib, palbociclib, everolimus, olaparib CSK SSL via CSK 1
bevacizumab, dasatinib, placebo CSK SSL via CSK 1
ce-mark approved laa closure devices, acetylsalicylic acid, clopidogrel, dabigatran, rivaroxaban, apixaban, edoxaban, phenprocoumon, warfarin TP53 SSL via TP53 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride CSK SSL via CSK 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method CSK SSL via CSK 1
dasatinib, laboratory biomarker analysis, physiologic testing CSK SSL via CSK 1
dasatinib, mfolfox6 CSK SSL via CSK 1
dasatinib, pharmacological study CSK SSL via CSK 1
dasatinib, temozolomide, placebo, radiation therapy CSK SSL via CSK 1
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.